RxDoctor Payments Data

Ezell Askew, MD

Interventional Pain Medicine · Lodi, CANPI 1699760769

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $60,304 of the $86,564 with a category attached, or 69.7%. 32 manufacturers reported payments, led by Flowonix Medical Incorporated at 43.6% of the total. Reporting peaked in 2019 at $44,302 and has fallen 85.5% since, to $6,402 in 2025. Among interventional pain medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$86,564in general payments, 2019–2025

Across 366 payments — averaging $236.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Flowonix Medical Incorporated$38K
  • Nevro Corp.$28K
  • Medtronic$8K
  • Globus Medical$4K
  • Philips North America LLC$3K
  • Boston Scientific$2K
  • plus $5K from 26 others
$2,500in research payments, 2019–2025

Across 1 payment — averaging $2500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Globus Medical$3K

What the payments were for

  • Consulting fees$60,30470%
  • Speaking & faculty fees$11,01313%
  • Travel & lodging$7,0178%
  • Food & beverage$8,23010%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$86,564 in reported general payments places this provider in the 90th percentile of 188 interventional pain medicine providers in California.

See all interventional pain medicine providers in California

Medicare billing

Part B allowed, 2024
$1,095,122
Medicare patients
417
Services billed
26,622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tizanidine Hcl56$230
ClopidogrelClopidogrel Bisulfate16$43

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Lodi

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →